Stocks in news:

• Board meetings:
  GSK Pharma CY07 audited results
  Megasoft, Vesuvius India results
• Rel power board meet is on Sunday for bonus
• HDFC Bank, Centurion BoP board meet on Saturday to consider merger proposal - ET
• Tata Motors JLR bid drives shareholders to sell stocks, A S Thiyaga Rajan sells 99% of its holding in Tata Motors, says integrating the acquisition is not going to be easy - Agencies
• V-Guard Industries IPO subscribed 2.70 times
• REC IPO closes today; subscribed 4.13 times till now
• NSE launches S&P CNX 500 Shariah and S&P CNX Nifty Shariah index
• Amtek Auto forms 50:50 JV with American Railcar Industries for railcar manufacturing
• Deccan Aviation board approves FCCB / ADR / GDR issue up to Rs 1600 cr
• SAIL forms 26:74 JV with JP Associates to set up 2 mt cement plant at Bokaro
• CHD Developers to set up new project in Haridwar; to generate revenue of Rs 100-105 cr over 2 years
• Alstom Projects bags 2 export orders worth Rs 592 cr
• HCC forms wholly owned subsidiary HCC Infrastructure for infrastructure development projects
• RBI allows FIIs to buy up to 40% in Info Edge
• Tata's may keep loss-making Jaguar off its books post the deal and only look to integrate Land Rover - ET
• Haryana govt sues REL for delay of power plant - HT
• Dutch court bars Ranbaxy's Lipitor launch - Agencies
• Anand Jain (Jai Corp) plans global fund, eyes Dubai project - ET
• Birla group in race for GE Money's loan biz, Reliance Cap exits - ET
• Steel Future on LME from Monday
• PNB, Vijaya Bank to exit JV with US based Principal Financial Group - BS
• MGF, Adlabs among 25 others in race for development of Delhi's Chanakya Cinema - Mint
• RBI allows FIIs to buy up to 40% in Tulip IT & 49% in Tourism Finance
• Exclusive:
  JLR Union and Tata Mgmt meeting over, meeting conclusive: Sources
  Union says MoU between Tata Motors & Ford to be signed around 5th/6th March
• SEBI Gives Initial Nod To Indiabulls Fin To Set Up Mutual Fund
• Exclusive
  US FDA Inspects Ranbaxy's MP Based Dewas Manufacturing Plant: Srcs
  Report On Ranbaxy's Dewas Plant Inspection Expected In Few Weeks: Srcs
  Ranbaxy Not Available For Comment On Plant Inspection By US FDA: Srcs